Abstract: Embodiments of the present disclosure are directed towards formulated polyol compositions that include a first polyether polyol having an average hydroxyl number from 112 to 280 mg KOH/g, a second polyether polyol having an average hydroxyl number from 18.5 to 51 mg KOH/g, a third polyether polyol having an average hydroxyl number from 20 to 70 mg KOH/g, and at least one of: fourth polyether polyol having an average hydroxyl number from 112 to 280 mg KOH/g; and a methoxypolyethylene glycol having an average hydroxyl number from 56 to 190 mg KOH/g.

Abstract: The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

Abstract: A method and system for the identification of a user is provided, the system having: an enrollment processor, whereby initial login attempts by the user are measured, and data identifying the user are collected for a specific device and location; the enrollment processor being configured to collect the identifying data and create a first login score, a iterative average login score, and a iterative standard deviation login score; an enrolled login processor, the enrolled login processor being configured to measure dwell time on keys and flight time between keys in a login sequence and to calculate weighted dwell time and weighted flight time from the dwell time and the flight time; a login score calculator, the calculator taking the weighted flight time and the weighted dwell time and generating an actual login score; a login confidence comparator, the login confidence comparator comprising a processor whereby a comparison score is generated as a function of the actual login score, the iterative average login